Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-23
2005-08-23
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S087000, C546S086000, C546S085000, C546S080000, C514S291000
Reexamination Certificate
active
06933303
ABSTRACT:
This invention provides compounds which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases, the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease.
REFERENCES:
patent: 6069150 (2000-05-01), Spinelli et al.
patent: WO 92/04348 (1992-03-01), None
patent: WO 98/56376 (1998-12-01), None
patent: WO 99/46244 (1999-09-01), None
Ishida, J. et al.: Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs. Bioorg. & Med. Chem. Lett. vol. 9, pp. 3319-3324, 1999.
Brossi, A. et al.: Alkaloids in mammalian tissues. J. Med. Chem. vol. 16, pp. 418-420, 1973.
Deveau, et al., “The Synthesis of Amino-Acid Functionalized B-Carbolines as Topoisomerase II Inhibitors” Bioorganic & Medicinal Chem. Ltrs.II, pp. 1251-1255 (2001).
Fantauzzi, et al., “Synthesis of Diverse Tetrahydro-B-Carboline3-Carboxamides and -2,3-Bis-lactams On a Versatile 4-Hydroxythiophenol-Linked Solid Support”, Tetrahedron Letters, vol. 39 pp. 1291-1294 (1998).
PCT International Search Report for PCT/US02/33520.
Iversen, L.F., et al., Steric Hindrance as a Basis for Structure-Based Design of Selective Inhibitors of Protein-Tyrosine Phosphatases, Biochemistry, 2001, 40, No. 49, 14812-14820.
Bleasdale, J.E., et al., Small Molecule Peptidomimectics Containing a Novel Phosphotyrosine Bioisostere Inhibit Protein Tyrosine Phosphatase 1B and Augment Insulin Action, Biochemistry, 2001, 40, 5642-5654.
Shim, Y.S., et al., Formylchromone Derivatives as a Novel Class of Protein Tyrosine Phosphatase 1B Inhibitors, Bioorganic & Medicinal Chemistry Letters, 13, (2003) 2561-2563.
Cheon, H.G., et al., Discovery of a Novel Protein Tyrosine Phosphatase-1N Inhibitor, KR61639: Potential Development as an Antihyperglycemic Agent, European Journal of Pharmacology, 485 (2004) 333-339.
Urbanek, R.A., et al., Potent Reversible Inhibitors of Protein Tyrosine Phosphatase CD45, J. Med. Chem., 2001, 44, 1777-1793.
Umezawa, K., et al., Molecular Design and Biological Activities of Protein-Tyrosine Phosphatase Inhibitors, Pharmacology & Therapeutics, 99, (2003), 15-24.
Sarmiento, M., et al., Structure-Based Discovery of Small Molecule Inhibitors Targeted to Protein Tyrosine Phosphatase 1B, J. Med. Chem., 2000, 43, 146-155.
Andrews Robert C.
Mjalli Adnan M. M.
Ren Tan
Xie Rongyuan
Yarragunta Ravindra R.
Kilpatrick & Stockton
TransTech Pharma, Inc.
LandOfFree
Heteroaryl-fused nitrogen heterocycles as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl-fused nitrogen heterocycles as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl-fused nitrogen heterocycles as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3519188